<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Dabigatran etexelate is a new oral direct thrombin inhibitor that has been approved by the US Food and Drug Administration to prevent <z:hpo ids='HP_0001297'>stroke</z:hpo> in patients with nonvalvular <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>A 51-year-old man with a history of <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> who was taking dabigatran presented with an <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The patient had a <z:mpath ids='MPATH_458'>normal</z:mpath> international normalized ratio, activated partial thromboplastin time, and an elevated thrombin time of 26.4 seconds </plain></SENT>
<SENT sid="3" pm="."><plain>Recanalization of the middle cerebral artery with intravenous tissue plasminogen activator was apparent on digital subtraction angiography, and there was no evidence of <z:hpo ids='HP_0001342'>intracerebral hemorrhage</z:hpo> on the repeat computed tomographic scan </plain></SENT>
<SENT sid="4" pm="."><plain>This is the first report of a patient who was taking dabigatran etexilate and who had an <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> caused by a middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, with an elevated thrombin time and radiographic recanalization with intravenous tissue plasminogen activator without evidence of hemorrhagic transformation </plain></SENT>
</text></document>